Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over....
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on difelikefalin (Kapruvia) for pruritus in adults with chronic kidney disease having haemodialysis....
Six digitally enabled therapies can be used as treatment options for
adults with anxiety disorders while further evidence is generated on their
clinical and cost effectiveness, once they have appropriate approval.
The following technologies can only be used once they have Digital
Technology Assessment Cr...
Three digitally enabled therapies can be used as treatment options for
adults with depression while further evidence is generated on their
clinical and cost effectiveness. The therapies should be used with
support from a trained practitioner or therapist in NHS Talking Therapies
for anxiety and depressio...
Athanazio, Rodrigo Abensur;
Tanni, Suzana Erico;
Ferreira, Juliana;
Fuccio, Marcelo de;
Marostica, Paulo José Cauduro;
Ferreira, Juliana;
Dalcin, Paulo de Tarso Roth;
Esposito, Concetta;
Canan, Mariane Gonçalves Martynychen;
Coelho, Liana Sousa;
Firmida, Mônica de Cássia;
Almeida, Marina Buarque de;
Monte, Luciana de Freitas Velloso;
Souza, Edna Lúcia;
Pinto, Leonardo Araujo;
Rached, Samia Zahi;
Oliveira, Verônica Stasiak Bednarczuk de;
Riedi, Carlos Antonio;
Silva Filho, Luiz Vicente Ribeiro Ferreira da.
A fibrose cística (FC) é uma doença genética que resulta em disfunção da proteína
reguladora de condutância transmembrana da FC (CFTR), que é um canal de cloro e
bicarbonato expresso na porção apical de células epiteliais de diversos órgãos. A
disfunção dessa proteína resulta em manifest...
Amer, Marwa;
Alshahrani, Mohammed;
Arabi, Yaseen;
Al‑jedai, Ahmed;
Alshaqaq, Hassan M;
Al‑Sharydah, Abdulaziz;
Al‑Suwaidan, Faisal A;
Aljehani, Hosam;
Nouh, Thamer;
Mashbari, Hassan;
Tarazan, Nehal;
Alqahtani, Saad;
Tashkandi, Wail;
Maghrabi, Khalid;
Albugami, Muneerah;
Albugami, Muneerah;
Hashim, Samaher;
Alsubaie, Norah M;
Alsenani, Mohammad;
Algethamy, Haifa;
Alshammari, Thamir M;
Alaklabi, Ali;
Ismail, Nadia;
Altawil, Esraa S;
Elhazmi, Alyaa;
Nahhas, Ahmed;
Aljuaid, Maha;
Alsadoon, Naif;
Binbraik, Yasser;
Yuan, Yuhong;
Alhazzani, Waleed.
To develop evidence-based clinical practice guidelines on venous thromboembolism (VTE) prevention in adults with trauma in inpatient settings. The Saudi Critical Care Society (SCCS) sponsored guidelines development and included 22 multidisciplinary panel members who completed conflict-of-interest forms. ...
People with BRCA mutation-positive HER2‑negative high-risk early breast cancer usually have chemotherapy followed by surgery (neoadjuvant chemotherapy), or surgery followed by chemotherapy (adjuvant chemotherapy).
Clinical trial evidence shows that, compared with placebo, olaparib after neoadjuvant or...
This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
